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Abstract
OBJECTIVES: Overall, emphysema (EMP) is the most common indication for lung transplantation. The majority of patients present with
chronic obstructive pulmonary disease (COPD) and less frequently with alpha-1 antitrypsin deﬁciency (A1ATD). We analysed the results of
lung transplants performed for EMP in order to identify the impact of age on short- and long-term outcome.
METHODS: A retrospective analysis was undertaken of the 108 consecutive lung transplants for EMP performed at our institution from
November 1992 to August 2013 (77 COPD, 31 A1ATD). Retransplantations were excluded.
RESULTS: The median age was 56 years (range 31–68). Thirty-day mortality rate was 3.7%. One- and 5-year survival rates in COPD and
A1ATD recipients were comparable (P = 0.8). The 1- and 5-year survival rates for recipients aged <60 years old were signiﬁcantly better
than the age group of ≥60 years (91 and 79 vs 84 and 54%, P = 0.05). Since 2007, the 1- and 5-year survival for these two age groups were
96 and 92 vs 86 and 44%, respectively, P = 0.04, log-rank test). For the following parameters, we were not able to ﬁnd any difference to
affect survival rates: use of intraoperative extracorporeal membrane oxygenation, waiting list time, sex, graft size reduction, body mass
index and diagnosis. In multivariate analysis, age at transplantation (≥60 years old) (HR 2.854; 95% conﬁdence interval (CI) 1.338–6.08,
P = 0.008) and unilateral lung transplantation (HR 15.2; 95% CI 3.2–71.9, P = 0.009) were independent risk factors for mortality.
CONCLUSIONS: COPD and A1ATD recipients have similar overall long-term survival. Recipients aged ≥60 years and unilateral lung trans-
plants were risk factors for mortality.
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INTRODUCTION
Chronic obstructive pulmonary disease [COPD, emphysema
(EMP) related to smoking] is overall the most common indication
for adult lung transplantation [1]. If we include EMP related to
alpha 1-antitrypsin deﬁciency (A1ATD), the proportion increases
to 40% of all lung transplants performed worldwide [1]. Although
more than 14 000 lung transplants were performed till June 2012,
there are still questions regarding the appropriate timing of the
procedure in the natural history of EMP, the type of procedure
and aspects of quality of life [1, 2].
The currently accepted recommendations for the timing of re-
ferral for lung transplantation are based on an expected survival
beneﬁt, which means that post-transplant survival should exceed
expected survival without transplantation [3, 4]. Survival beneﬁt of
lung transplantation, particularly in patients with cystic ﬁbrosis,
idiopathic pulmonary ﬁbrosis and primary pulmonary hyperten-
sion has been reported [5]. Although the studies demonstrated
survival beneﬁt of transplantation for EMP, there are also studies
that did not show any survival beneﬁt for EMP [6, 7].
Most of the studies focused on the type of procedure (unilateral
versus bilateral) and/or type of the diagnosis namely COPD versus
A1ATD [3, 8–13]. In the present study, we analysed the results of
lung transplants performed for EMP in order to identify the
impact of age on short- and long-term outcome.
MATERIALS ANDMETHODS
We performed a retrospective review of prospectively collected
data of 108 recipients undergoing lung transplantation for EMP
from November 1992 to August 2013 at the University Hospital
Zurich. The diagnosis was COPD in 77 and A1TTD in 31 recipients.
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Retransplantations were excluded. Sensor date for survival analysis
was 3 November 2013. Follow-up was complete in all patients
with a median of 36 months [interquartile range (IQR), 14–100].
Data analysis
Statistical analysis was performed using the Statistical Package for
the Social Science, IBM SPSS Statistics version 21.0 (IBM Corp.,
Armonk, NY, USA). Continuous variables are shown as median
(IQR). Kaplan–Meier analysis was used to calculate actuarial sur-
vival. The log-rank test was used to test the difference in Kaplan–
Meier survival curve between the groups. Cox regression method
was used for multivariate analysis. A P-value less than 0.05 was
considered the threshold value for statistical signiﬁcance.
RESULTS
Patient characteristics and perioperative data are given in Table 1.
Lung volume reduction surgery (LVRS) prior to transplantation was
performed in 45 cases (42%), 34 in COPD and 11 in A1ATD.
Forced expiratory volume in one second (FEV1) at 1 year was
2.83 l (% predicted 95%) (IQR, 1.3 l). FEV1 at 5-year was 2.46 l
(% predicted 81%) (IQR, 1.59 l)
For the whole group (n = 108), 45 patients underwent LVRS and
63 did not receive LVRS before lung transplantation. One-year sur-
vival for recipients who underwent LVRS was 91 versus 87% for
those who did not receive LVRS before lung transplantation
(P = 0.4, long-rank test). If we take the era since 2007 (n = 51), 1-year
survival for recipients who underwent LVRS (n = 26) was 96 versus
87% for those who did not receive LVRS (n = 25) before lung trans-
plantation (P = 0.7, long-rank test). Thirty-day mortality between
these patients (2 deaths in each group) was comparable (P = 0.7).
At 1-year post-transplant, 64% (7/11) were free of Chronic Lung
Allograft Dysfunction (CLAD) in unilateral transplanted patients,
9% (1 patient) had CLAD and 27% (3 patients) were deceased. At
5-year post-transplant, 54% of unilateral transplanted patients
were free of CLAD and 45% had died (all-cause mortality). None
of the patients ≥60 underwent unilateral lung transplantation.
At 1-year post-transplant, 84% (81/96) of the bilateral trans-
planted patients were free of CLAD, 4% (4 patients) had CLAD and
12% (11 patients) were deceased (all-cause mortality). In patients
≥60 who underwent bilateral lung transplantation (BLT), 23 were
free of CLAD, 3 had CLAD. Five patients died (only 1 due to CLAD)
in this age group. This means that 75% of CLAD (3/4) and 45% (5/11)
of deaths occurred in the older COPD recipients (≥60 years old)
At 5-year post-transplant, 39% (27/69) of bilateral transplanted
patients were free of CLAD, 26% (18 patients) had CLAD and 35%
(24 patients) were deceased (all-cause mortality). Twenty-seven
patients were alive but had not yet reached the 5-year time-point.
For the age group ≥60 years, 4 were free of CLAD and 4 had
CLAD. Twelve patients died in this group at 5 years. This means
that 22% of CLAD (4/18) and 50% (12/24) of deaths occurred in
older COPD patients (≥60 years old). This contribution of the
elderly to the frequency of CLAD and mortality needs to be
viewed in the light of the fact that only 30% of patients (32/107)
belonged to the group transplanted at age ≥60.
Postoperative complications are given in Table 2. Thirty-day
mortality rate was 3.7%.
One- and 5-year survival rates in COPD and A1ATD recipients
were comparable (P = 0.8, log-rank test).
The 1- and 5-year survival rates for recipients aged <60 years
were signiﬁcantly better than the age group of ≥60 years old (91
and 79 vs 84 and 54%, P = 0.05, log-rank test). Since 2007, 1- and
5-year survival for these two age groups were 96 and 92 versus 86
and 44%, respectively, P = 0.04, log-rank test) (Fig. 1).
Applying univariate analysis, use of intraoperative extracorporeal
membrane oxygenation, waiting list time, sex, size reduction, body
mass index and diagnosis were not found to inﬂuence mortality
(Table 3). Age at transplantation (≥60 years old) and unilateral lung
transplantation were found to be risk factors for mortality (Table 4).
As seen in Table 5, none of the patients older than 60 years had
undergone unilateral lung transplantation excluding the problems
that might have been associated with morbidity and mortality.
Table 1: Perioperative patient characteristics
COPD n = 78 (72%)
A1ATD n = 30 (28%)
Female/male n = 50/58
Age (years) 56 (51–60)
Preoperative FEV1 (l) 0.6 (0.52–0.86)
BMI (kg/m2) 21 (19–24)
Waiting list time (days) 165 (67–286)
Donor variables
Female/male n = 37/71
Age (years) 50 (37–57)
PaO2/FiO2 (kPa) 43 (26–56)
Perioperative data
Bridge to LuTx on ECMO n = 3
Bridge to LuTx on MV n = 1
Intraoperative ECMO/CPB n = 22 (20%)
Unilateral LuTx n = 11 (10%)
Bilateral LuTx n = 97 (90%)
Lobar LuTx n = 18
CIT (right) (min) 215 (179–273)
CIT (left) (min) 314 (260–375)
Total operation time (min) 372 (300–436)
ICU time (days) 4 (2–7)
FEV1 at discharge (l) 2.3 (1.7–2.7)
Data are presented as number (%) or median (interquartile range).
COPD: chronic obstructive pulmonary disease; A1ATD: alpha-1
antitrypsin deficiency; BMI: body mass index; l: litre; FEV1: forced
expiratory volume in one second; kPa: kilopascal (1 kPa = 7.5 mmHg),
ECMO: extracorporeal membrane oxygenation; MV: mechanical
ventilation; CBP: cardiopulmonary bypass; LuTx: lung transplantation;
CIT: cold ischaemic time; min: minutes; ICU: intensive care unit.
Table 2: Postoperative complications (n)
Tracheotomy 11
Haemothorax (<10 days) 7
Haemothorax (>10 days) 6
Pneumothorax 9
Late pleural effusion 3
PGD (Grade 2–3, T48/72) 6
Lymphocele 5
Phrenic nerve injury 1
Thoracic hernia 1
Technical complications 6
Abdominal complications 15
PGD: primary graft dysfunction; n, number.
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DISCUSSION
According to the recent International Society for Heart and Lung
Transplantation (ISHLT) Registry Report, 14 784 lung transplants
were performed for EMP (n = 12 602) and A1ATD (n = 2182) [1].
Single lung transplantation (SLT) was performed in 49.8%, and BLT in
33%. Between 1997 and 2001, only 28% of transplants performed
for EMP were BLTs. Thereafter, beginning with 2013, the number of
BLTs increased steadily reaching 72% in 2011 [1]. The ISHLT Registry
reports a 6.9 years of median survival in recipients that received BLT
compared with 4.6 years in SLT recipients [1]. These rates increase to
9.6 years in BLT recipients and 6.5 years in SLT recipients who
survive the ﬁrst year following transplantation [1].
BLT is preferred by the most centres, as native lung hyperinﬂation
post-SLT might be responsible for the inferior results of SLTs [14,
15]. However, SLT has shorter total ischaemia and operation time
resulting in lower perioperative morbidity and mortality rates [16].
Other reasons for supporting SLT are reduction of the donor organ
shortage and decreased waiting list morbidity and mortality [16].
In a retrospective study, Sundaresan et al. [9] reported that reci-
pients who underwent BLT or SLT had comparable morbidity and
mortality rates. In this series, overall hospital mortality was 6.2%
[9]. The authors did not ﬁnd any difference in hospital stay, inten-
sive care unit stay or duration of mechanical ventilation between
BLT and SLT recipients. However, 5-year survival in BLT recipients
was 53% compared with 41% in SLT recipients [9]. In another
study, Cassivi et al. [10] reported a 5-year survival rate of 66.7% in
BLT and 44.9% in SLT recipients, respectively. On the other hand,
Delgado et al. from Spain demonstrated comparable 5-year sur-
vival rates, 59% for SLT and 56% for BLT. The frequency of bron-
chiolitis obliterans syndrome was 34% in SLT and 42% in BLT [11].
Thabut et al. [12] compared survival after both SLT and BLT in
EMP patients by analysing data from ISHLT Registry data. The
Figure 1: Survival by two age groups (<60 years old versus 60 years old) for
patients with emphysema who underwent lung transplantation since 2007. The
1- and 5-year survival for these two age groups were 96 and 92 versus 86 and
44%, respectively, P = 0.04 (log-rank test).
Table 3: Univariate analysis showing hazard of death following lung transplantation in emphysema recipients (n = 108)
Variable Coefficient Standard error Hazard ratio 95% CI 95% CI P-value
Lower Upper
Sex −0.438 0.332 0.645 0.336 1.238 0.187
Waiting List time 0.000 0.001 1 0.998 1.001 0.649
Size reduction 0.133 0.477 1.143 0.449 2.908 0.78
Diagnosisa 0.126 0.372 1.134 0.547 2.354 0.735
BMI 0.016 0.037 1.016 0.945 1.092 0.6
ECMO useb 0.477 0.425 1.612 0.701 3.707 0.261
Age groupc 1.127 0.399 3.085 1.413 6.739 0.005
Unilateral LuTx 3.553 0.919 34.932 5.764 211.68 0.000
BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LuTx: lung transplantation.
aCOPD versus A1ATD.
bIntraoperative ECMO or cardiopulmonary bypass use.
c≥60 years old.
Table 4: Multivariate analysis for hazard of death following lung transplantation in emphysema recipients (n = 108)
Variable Coefficient Standard error Hazard ratio 95% CI 95% CI P-value
Lower Upper
ECMO usea 0.5 0.43 1.652 0.71 3.839 0.24
Age groupb 1.04 0.386 2.854 1.338 6.088 0.008
Unilateral LuTx 2.725 0.792 15.249 3.231 71.967 0.009
BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LuTx: lung transplantation.
aIntraoperative ECMO or cardiopulmonary bypass use.
b≥60 years old.
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median survival after either type of lung transplants for patients
with EMP was 5.0 years. The proportion of patients who had BLT
increased from 22% in 1993 to 56% in 2006. Median survival time
after BLT was longer than after SLT. However, BLT had little beneﬁt
compared with SLT for patients who were ≥60 years old. These
authors concluded that BLT leads to longer survival than SLT in
patients with EMP, especially those who are <60 years old [12].
Meyer et al. [13] analysed 2260 lung transplant recipients with
EMP recorded in the ISHLT/United Network for Organ Sharing
Thoracic Registry between January 1991 and December 1997. The
multivariate model showed a higher risk ratio for mortality in patients
aged 40–57 years who received SLT versus BLT. They concluded that
SLT might offer acceptable early survival rates for patients with end-
stage respiratory failure. However, long-term survival data favour BLT
in younger recipients until approximately 60 years old. Their
reported data suggest that a BLT approach offers a signiﬁcant survival
advantage to recipients younger than 60 years old [13].
The superiority of BLT over SLT has also been shown in a multi-
centre study [17]. From these studies, it can be concluded that BLT
has similar short-term results compared with SLT, but superior
intermediate and long-term results [18].
Other than the survival advantage shown in prior studies, there
are other facts for performing BLT in patients with EMP [18].
Hyperinﬂation of the native lung was reported to occur in 5–15% of
patients after SLT, sometimes requiring LVRS [19–21]. Pneumonia in
the native lung occurs in 10–20% of patients, and with a mortality
rate up to 20% of those patients who develop this complication
[22, 23]. Development of lung cancer in the native lung was
reported to be2–3% of patients [24].
On the other hand, Hadjiliadis and Angel [18] reported that SLT
might be beneﬁcial for patients with EMP if they develop severe
primary graft dysfunction. These patients might still have a func-
tioning emphysematous lung that could potentially sustain
patients while primary graft dysfunction resolves [18].
In conclusion, our data show that recipients aged ≥60 years old
and unilateral lung transplants were risk factors for mortality.
Patients younger than 60 years old should be offered BLT in order
to achieve survival beneﬁt for EMP recipients.
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Table 5: Cause of death in emphysema recipients
undergoing lung transplantation shown for the two age
groups
Cause of death (n = 50) Age at LuTx Total
<60 years ≥60 years
Respiratory infection 6 (1)a 4 10
Gastrointestinal perforation or
haemorrhage
6 3 9
Multiorgan failure 4 (2) 3 7
Allograft dysfunction/failure 6 (3) 1 7
Kidney failure 3 (1) 1 4
Cerebral infarction or haemorrhage 3 1 4
Malignancy 3 (2) 3
Cardiac failure 2 2
Sepsis 2 (1) 2
Unknown 1 (1) 1 2
LuTx: lung transplantation.
aNumbers in parenthesis indicate unilateral lung transplantation.
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